SEC Form 4 · accession 0001387131-15-000872
Ohr Pharmaceutical Inc · OHRP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Scott Slakter
Director
Period of report
Mar 10, 2015
Accepted (ET)
Mar 12, 2015 · 4:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001173281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per share | holding | — | — | — | 64,573 | D | ||
| Common Stock, par value $0.0001 per share | holding | — | — | — | 425,505 | I | By SKS Ocular, LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionF2,F1 | $10.14 | Mar 10, 2015 | A | 50,000 | A | Mar 10, 2015 | Mar 20, 2020 | Common Stock | 50,000 | 50,000 | D |
| Warrant | $2.85 | holding | — | — | — | May 18, 2012 | May 18, 2015 | Common Stock | 16,667 | 16,667 | D |
Explanation of responses
- F137,500 options are currently unexercisable; 1/3rd will become exercisable on each of March 10, 2016, March 10, 2017 and March 10, 2018.
- F2Options granted pursuant to registrant's 2014 Stock Incentive Plan.